Stem Cell Research: Diabetes

Whether you’re looking at  Type 1 or Type 2 diabetes, stem cells are showing some serious promise. Let’s break down the latest trials, studies, and expert opinions to see what the buzz is all about!

If you want to know more about the actual treatment process for diabetes, our article goes into more depth here. Or, speak to our team. They can guide you in deciding if it’s the right fit, help you choose the best clinic & region, and even assist you in securing some great discounts! Fill in our form here to set up a conversation.

Current Trials

1. CiPSC Islet Transplant Study (2024)

• Participants: 1 (so far)
• Current Phase: Phase I
• Details: Picture this: a Type 1 diabetes patient goes from insulin injections to zero in 75 days, thanks to CiPSCs. Yep, that’s what happened here. The patient’s blood sugar stayed stable for a whole year. Sounds amazing, right? But hold on—we need more patients and more time before we pop the champagne. It’s still early.

2. Vertex Study (VX-880)

• Participants: 17
• Current Phase: Phase 1/2
• Details: In this U.S.-based trial, Type 1 diabetes patients are getting stem cell-derived beta cells. The exciting part? Some participants are already cutting back or completely ditching their insulin shots. More data is on the way, but so far, the results are making waves.

3. Mesenchymal Stem Cell (MSC) Study (China)

• Participants: 60
• Current Phase: Phase 1/2
• Details: Over in China, they’re checking out mesenchymal stem cells (MSCs) to see if they can improve insulin sensitivity and reduce inflammation for Type 2 diabetes patients. The early feedback? Less inflammation and better insulin function—good signs, but we’ll need more research to know for sure.

4. P421 Hypoimmune Islet Cell Transplant (2025)

• Participants: Ongoing
• Current Phase: First-in-human study
• Details: Scientists at Sana Biotechnology are testing a new stem cell treatment for Type 1 diabetes that could eliminate the need for insulin shots—without requiring immune-suppressing drugs. Normally, when people get donor islet cells (the ones that produce insulin), their immune system attacks them. But Sana’s treatment, UP421, uses special gene editing to make these cells invisible to the immune system, meaning the body won’t reject them.
  
  In this study, doctors at Oslo University Hospital transplanted the cells into the forearm (yes, the forearm—not the pancreas!). The goal? To see if the new cells survive, function, and produce insulin without the need for immunosuppressants.
  
  Results so far:
• The cells survived: Four weeks after transplant, doctors found the cells were still alive and producing insulin.
• They responded to food: Blood tests showed that insulin levels increased after meals, proving the cells were working.
• The cells stayed in place: MRI scans confirmed that the transplanted cells hadn’t died off or disappeared.
• No immune attack: The patient’s immune system didn’t reject the cells, even without immune-suppressing drugs.
  
  Why It Matters:
• No immune-suppressing drugs needed → This is a big deal because most islet cell transplants require lifelong medication to stop the body from attacking them.
• First time this has worked in humans → If this keeps working, it could lead to off-the-shelf stem cell treatments for Type 1 diabetes.
• Next steps: The company is now working on SC451, a version of these cells that could be made from stem cells instead of deceased donors—making the treatment even more accessible.

5. AlloStem (CELZ-201) for Type 2 Diabetes

• Participants: 20
• Current Phase: Phase 1/2 clinical trial
• Details: AlloStem is a stem cell therapy developed by Creative Medical Technology Holdings, Inc., aimed at reducing insulin dependency in Type 2 diabetes patients. It uses allogeneic (donor-derived) perinatal stem cells, designed to help repair pancreatic function, reduce inflammation, and improve insulin sensitivity.
  
  The goal is to see if infusions of AlloStem cells can restore natural insulin production, offering a long-term alternative to traditional insulin therapy.
• Results So Far (Announced February 2025):
  – 80% of patients reduced their insulin dependency after treatment.
  – Hemoglobin A1c levels stabilized, indicating better long-term blood sugar control.
  – No serious adverse effects reported, suggesting the treatment was well tolerated.
• Why It Matters:
  – Potential to delay or reduce insulin use → If successful, this could provide a regenerative approach to managing Type 2 diabetes instead of just controlling symptoms.
  – Allogeneic (off-the-shelf) treatment → Unlike autologous stem cell therapies, this doesn’t require a patient’s own cells, making it more accessible.
  – First-in-class therapy → There are few stem cell-based options for Type 2 diabetes, making this a groundbreaking trial.
• Next Steps:
  – The company plans to move forward with additional trials to validate safety and effectiveness in a larger patient group.
  – Further research will determine long-term benefits, optimal dosing, and potential regulatory approval.

Summary of Current Trials

So far, the CiPSC islet transplant and Vertex trials for Type 1 diabetes are giving us real reasons to be excited. Both are showing promise in reducing insulin needs. For Type 2 diabetes, the MSC study is showing early progress, but we still need more data before we can call it a game-changer.

What the Recent Data Tells Us

A major study analyzing 143 clinical trials worldwide (2000–2024) reveals:

1. Most Studies Are Still Early-Stage
   – 83.2% of trials are in Phase I or II.
   – Only 11.2% have reached Phase III/IV.
2. MSCs Dominate the Research Landscape
   – Mesenchymal Stem Cells (MSCs) – 52.4% of trials
   → Mostly used for Type 2 diabetes to improve insulin sensitivity.
   – Hematopoietic Stem Cells (13.3%)
   → Used in Type 1 diabetes to modulate immune responses.
   – iPSCs & ESCs (8.4% & 6.9%)
   → Potential for beta-cell regeneration, but long-term safety is unclear.
3. China Is Leading the Research
   – China accounts for 47 trials (33.3%), more than any other country
   – Why? The country is investing heavily in stem cell research

Previous Trials

1. Stem Cell Beta Cells for Type 1 Diabetes

• Participants: 30
• Current Phase: Completed
• Details: This study tested stem cell-derived beta cells on Type 1 diabetes patients. Some reduced their insulin use, but long-term results are still up in the air.

2. Hematopoietic Stem Cell Transplant (HSCT) for Type 1 Diabetes

• Participants: 20
• Current Phase: Completed
• Details: This Brazilian study explored HSCT to help the immune system stop attacking insulin-producing cells. Patients saw improvement, but the high risks involved have kept this from becoming a go-to treatment.

Summary of previous Trials

These earlier trials showed glimmers of success, but their small size and short follow-ups meant they didn’t change the game. However, they helped pave the way for today’s more advanced trials.

Reviews and Meta-Analyses

Meta Analysis (2023)

• Success Rate: This review focused on iPSCs and MSCs, showing some early success in regenerating insulin-producing cells. Exciting stuff for Type 1 diabetes patients.
  
• Criticism: But we still need bigger, longer human trials to really understand the safety and effectiveness of these treatments. The potential is there, but we’re not quite ready to roll out the red carpet.

Meta-Analysis From Iran

Criticism: Results weren’t consistent across all studies. Some patients saw great improvements, while others didn’t respond as well. More standardized protocols are a must to clear up the picture.

Success Rate: Some trials showed improved insulin production, particularly for Type 1 diabetes.

Conclusion

Stem Cell Therapy is shaping up to be a major player in diabetes treatment, especially for Type 1 diabetes. Trials like the CiPSC islet transplant and VX-880 are showing strong early success, while MSC therapy for Type 2 diabetes is still finding its footing. In all honestly, it is slightly early to say this is the answer we’ve been waiting for. If you are going to try Stem Cells for your diabetes, be aware we don’t know long term effects and the technology may not be fully developed yet.

If you are looking into Stem Cell Therapy, you might be deciding which country to go for. We’ve compiled an overview on the differences between treatment in different countries here.